Methods and compositions for treating thyroid-related medical conditions with reduced folates

• US 8,343,974 B2
• Filed: 07/09/2010
• Issued: 01/01/2013
• Est. Priority Date: 07/10/2009
• Status: Active Grant

• Current Assignee: Linzy O. Scott III
• Original Assignee: Linzy O. Scott III
• Inventors: Scott, Linzy O. III
• Primary Examiner(s): ALSTRUM ACEVEDO, JAMES HENRY
• Application Number:
  US12/833,933
• Publication Number:
  US 20110008464A1
• Time in Patent Office: 907 Days
• Field of Search: 514/249, 514/252.14
• US Class Current: 514/252.14
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/205 Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 31/59 Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
• CPC Class Codes: A61K 31/593 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
• CPC Class Codes: A61K 31/7056 containing five-membered rings with nitrogen as a ring hetero atom
• CPC Class Codes: A61K 31/714 Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
• CPC Class Codes: A61K 33/06 Aluminium, calcium or magnesium; Compounds thereof , e.g. clay
• CPC Class Codes: A61K 33/26 Iron; Compounds thereof
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 3/02 Nutrients, e.g. vitamins, minerals
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/00 Drugs for disorders of the endocrine system
• CPC Class Codes: A61P 5/14 of the thyroid hormones, e.g. T3, T4
• CPC Class Codes: A61P 5/16 for decreasing, blocking or antagonising the activity of the thyroid hormones
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/06 Antianaemics

Abstract

The present invention provides methods and compositions for treating thyroid-related medical conditions. Many thyroid-related medical conditions exist that go undiagnosed and untreated. These conditions may be prevented and treated with reduced folates and vitamin B12. Administration of reduced folates and vitamin B12 will prevent or treat cerebrospinal folate deficiency, which is linked to thyroid-related medical conditions. Administration of reduced folates and vitamin B12 will also prevent or treat conditions associated with masked megaloblastic anemia and hypothyroidism, and other conditions brought upon through improper thyroid function. Additionally, it is commonplace to treat many thyroid conditions with anti-thyroid drugs or thyroid stimulating drugs. This practice alone is also responsible for causing, or not beneficially addressing, adverse conditions that can be prevented or treated through the methods and compositions discussed herein.

Claims

1. A method of treating decreased folate in cerebrospinal fluid, comprising:

a. selecting an individual with hypothyroidism treated with a thyroid medication and who is in a medication induced euthyroid state; and

b. administering a composition comprising a folate to the individual.

2. The method of claim 1, wherein the folate is a reduced folate.

3. The method of claim 2, wherein the thyroid medication is a thyroid stimulating drug and the reduced folate is administered with vitamin B12 and the thyroid stimulating drug.

4. The method of claim 3, further comprising the administration of one or more of the following:

iron, L-carnitine, calcium, or vitamin D.

5. The method of claim 2, wherein the reduced folate is in a composition comprising a thyroid stimulating drug, vitamin B12, and one or more of the following:

iron, L-carnitine, calcium, or vitamin D.

6. The method of claim 1, wherein the folate is L-methylfolate.

7. The method of claim 6, wherein the thyroid medication is a thyroid stimulating drug and the L-methylfolate is administered with vitamin B12 and the thyroid stimulating drug.

8. The method of claim 7, further comprising the administration of one or more of the following:

iron, L-carnitine, calcium, or vitamin D.

9. The method of claim 6, wherein the L-methylfolate is in a composition comprising a thyroid stimulating drug, vitamin B12, and one or more of the following:

iron, L-carnitine, calcium, or vitamin D.

10. The method of claim 1, wherein the folate is in a composition comprising a thyroid stimulating drug, vitamin B12, and one or more of the following:

iron, L-carnitine, calcium, or vitamin D.

11. The method of claim 1, further comprising the administration of vitamin B12 to the individual.

12. The method of claim 1, wherein the individual has a masked megaloblastic anemia.

13. The method of claim 1, wherein the individual has a masked macrocytic anemia.

14. The method of claim 1, wherein the individual has a macrocytic anemia.

15. The method of claim 1, wherein the individual has hepatic dysfunction.

16. The method of claim 1, wherein the individual had hypothyroxinemia.

17. The method of claim 1, wherein the individual had radioactive iodine or radiation that affected the thyroid gland, or had surgery on the thyroid gland.

18. The method of claim 1, wherein the thyroid medication is a thyroid stimulating drug.

19. The method of claim 1, wherein the individual has a methylenetetrahydrofolate reductase polymorphism.

20. The method of claim 1, further comprising the administration of vitamin B12 and iron to the individual.

21. The method of claim 1, further comprising the administration of vitamin B12 and L-carnitine to the individual.

22. The method of claim 1, further comprising the administration of vitamin B12 and calcium to the individual.

23. The method of claim 1, further comprising the administration of vitamin B12 and vitamin D to the individual.

24. The method of claim 1, wherein the composition further comprises vitamin B12 and one or more of the following:

iron, L-carnitine, calcium, or vitamin D.

25. The method of claim 1, wherein the thyroid medication is a thyroid stimulating drug and the folate is administered with vitamin B12 and the thyroid stimulating drug.